Page 14 - Project Orbis News Today

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

To embed, copy and paste the code into your website or blog: The U.S. Food and Drug Administration (FDA) Oncology Center of Excellence recently published an overview of Project Orbis and the regulatory actions within the first year of its implementation (June 2019 to June 2020). Project Orbis is a global collaborative review program intended to facilitate faster patient access to high-impact cancer therapies and standardize pivotal oncology clinical trials. We previously reported the first simu...

Apply for a licence to market a medicine in the UK How to license a medicine for sale in the UK, including applications through national and international routes. From: Contents Print this page This guidance also covers licensing a medicine in Northern Ireland through the centralised, decentralised and mutual recognition European procedures. Which procedure to follow There are several routes to obtain a marketing authorisation in the United Kingdom (UK), Great Britain (England, Scotla...

AstraZeneca plc (LON:AZN)’s  Tagrisso (osimertinib) has been approved in the US for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after tumour resection with curative intent.  Tagrisso is indicated for EGFRm patients whose tumours have exon 19 deletions or exon 21 L858R mutations as detected by an approved test. The approval was granted under the US Food and Drug Administration’s (FDA) Real-T...

TAGRISSO Approved in the US for the Adjuvant Treatment of Patients With Early-Stage EGFR-mutated Lung Cancer Approval based on unprecedented results from the ADAURA Phase III trial where TAGRISSO WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s TAGRISSO ® (osimertinib) has been approved in the US for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after tumor resection with curative intent. TAGRISS...

ADDING MULTIMEDIA TAGRISSO Approved in the US for the Adjuvant Treatment of Patients With Early-Stage EGFR-mutated Lung Cancer Approval based on unprecedented results from the ADAURA Phase III trial where TAGRISSO WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s TAGRISSO ® (osimertinib) has been approved in the US for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after tumor resection with curati...

AstraZeneca’s Tagrisso (osimertinib) has been approved in the US for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after tumour resection with curative intent. Tagrisso is indicated for EGFRm patients whose tumours have exon 19 deletions or exon 21 L858R mutations as detected by an approved test. The approval was granted under the US Food and Drug Administration’s (FDA) Real-Time Oncology Revie...

FDA approves first adjuvant treatment for patients with non-small cell lung cancer Today, the U.S. Food and Drug Administration approved Tagrisso (osimertinib) as the first adjuvant treatment for patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation. Todays approval of Tagrisso demonstrates how additional research on therapies approved in later stages of cancer can eventually improve treatment options for patients in earlier stages. With this approval, p...

© Getty Images Transparency in the decisions that the FDA makes in its scientific review of drugs and biologics is an important element of FDA’s mission to protect the public health, particularly as we announce the agency’s decisions on COVID-19 vaccine submissions. As the research and development of vaccines and treatments for COVID-19 continue, I want to reaffirm the commitment of the FDA to transparency. We will publicly share information on FDA’s decisions, especially around Emergenc...

On December 18, 2020, the Food and Drug Administration approved osimertinib (TAGRISSO, AstraZeneca Pharmaceuticals LP) for adjuvant therapy after tumor resection in patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. Efficacy was demonstrated in a randomized, double-blind, placebo-controlled trial (ADAURA, NCT02511106) in patients with EGFR exon 19 deletions ...